Drug Trial Radar · NCT00974571
Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246)
Last checked: Nov 20, 2026Latest source record: Feb 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,365
Actual
Start
Nov 2001
Primary completion
May 2002
Study completion May 2002
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Sep 10, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 15 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the ability of montelukast to improve the signs and symptoms of perennial allergic rhinitis compared to placebo. Cetirizine is included in the study as an active control.
Conditions
- Perennial Allergic Rhinitis
Interventions
montelukast sodiumDrug
montelukast 10 mg tablet orally once daily at bedtime for 6 weeks
Comparator: cetirizineDrug
cetirizine 10 mg tablet orally once daily at bedtime for 6 weeks
Comparator: placeboDrug
placebo tablet orally once daily at bedtime for 6 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in Daytime Nasal Symptoms ScoreTime frame: Baseline and first 4 weeks of a 6-week treatment period
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.